Intracranial and Peripheral Inflammatory Biomarkers Predict Futile Recanalization After Endovascular Treatment
Authors:
- Adrien ter SchiphorstASAdrien ter Schiphorst
- Cyril DargazanliCDCyril Dargazanli
- Julien LabreucheJLJulien Labreuche
- Francesca RapidoFRFrancesca Rapido
- Christian JorgensenChristian Jorgensen
- Farida DjouadFarida Djouad
- Christophe HirtzCHChristophe Hirtz
- Gregory GascouGGGregory Gascou
- Pierre-Henri LefevrePLPierre-Henri Lefevre
- 1 July 2026
- journal article
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (7) , 2053-2064
Abstract
BACKGROUND: Futile recanalization (absence of functional independence despite successful endovascular treatment [EVT]) remains a limitation in the treatment of large vessel occlusion stroke. Inflammation has emerged as a key contributor to brain reperfusion injury. Leveraging EVT, we quantified a large panel of immunologic biomarkers in the intracranial and peri-procedural peripheral blood samples and probed their association with futile recanalization. METHODS: We conducted a prospective single-center cohort study of patients with anterior-circulation large vessel occlusion, successful EVT (modified Thrombolysis in Cerebral Infarction ≥2b), and no reocclusion. We sampled intracranial blood distal to the thrombus before recanalization and collected peripheral blood immediately before and after EVT, and at 24 hours post-EVT. We measured 37 immune-vascular biomarkers selected a priori, using immunoassays, and tested their associations with futile recanalization (90-day modified Rankin Scale score, 3–6) using rank-based tests with false discovery rate control. Biomarkers meeting a prespecified effect-size threshold (≥0.5) entered multivariable logistic regression models adjusted for age, baseline National Institutes of Health Stroke Scale score and Alberta Stroke Program Early Computed Tomography Score, intravenous thrombolysis use, and time from last known well to groin puncture. RESULTS: Among 177 enrolled patients, 139 patients were included (median age, 77 years; 41% women), and 64 (46%) had futile recanalization. Six biomarkers showed at least a medium effect size at ≥1 timepoints: IL (interleukin)-6 (pre-EVT, intracranial, and 24-hour post-EVT), IL-10 (pre-EVT and intracranial), IL-15 (pre-EVT), VEGFR1 (vascular endothelial growth factor receptor 1; pre-EVT and 24-hour post-EVT), VCAM-1 (vascular cell adhesion molecule-1; intracranial and post-EVT), and SAA (serum amyloid A; post-EVT). In adjusted multivariable analyses, futile recanalization remained associated with VCAM-1 intracranially (adjusted odds ratio [aOR], 1.84 [95% CI, 1.11–3.05]) and post-EVT (aOR, 2.08 [95% CI, 1.03–4.19]), IL-10 pre-EVT (aOR, 3.87 [95% CI, 1.58–9.43]) and intracranially (aOR, 4.84 [95% CI, 1.68–13.90]), IL-15 pre-EVT (aOR, 1.60 [95% CI, 1.00–2.53]), and SAA post-EVT (aOR, 7.08 [95% CI, 1.95–25.59]). CONCLUSIONS: A core set of immune-vascular mediators measured in blood, both intracranially and peripherally, after EVT predicted futile recanalization. These findings support biomarker-guided risk stratification and motivate trials targeting microvascular inflammation.Keywords
This publication has 50 references indexed in Scilit:
- Targeting lipid nanoparticles to the blood-brain barrier to ameliorate acute ischemic strokeMolecular Therapy, 2024
- Systemic Immune-Inflammation Response is Associated with Futile Recanalization After Endovascular TreatmentNeurocritical Care, 2024
- Baseline severity and soluble vascular cell adhesion molecule 1 (sVCAM-1) as biomarker predictors of short-term mortality in acute ischemic strokeMetabolic Brain Disease, 2022
- Immune-inflammatory, coagulation, adhesion, and imaging biomarkers combined in machine learning models improve the prediction of death 1 year after ischemic strokeClinical and Experimental Medicine, 2021
- Peptide-based nanosystems for vascular cell adhesion molecule-1 targeting: a real opportunity for therapeutic and diagnostic agents in inflammation associated disordersJournal of Drug Delivery Science and Technology, 2020
- Interleukin 15 blockade protects the brain from cerebral ischemia-reperfusion injuryBrain, Behavior, and Immunity, 2018
- Role of interleukin-10 in the neuroprotective effect of the Angiotensin Type 2 Receptor agonist, compound 21, after ischemia/reperfusion injuryEuropean Journal of Pharmacology, 2017
- Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trialsThe Lancet, 2016
- Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)The Lancet, 1998
- IL-10 reduces rat brain injury following focal strokeNeuroscience Letters, 1998